Nexvet Announces Collaboration and Distribution Agreement with Virbac

/in ,

DUBLIN, Ireland; MELBOURNE, Australia –‐ December 3, 2014. Link here. Veterinary biologic therapy developer Nexvet Biopharma today announced the signing of a ten year collaboration and distribution agreement with Virbac (EPA:VIRP), one of the largest animal health dedicated companies in the world. Under the terms of the agreement, Virbac will distribute NV-01, Nexvet’s most advanced product, […]

Read more

SeaDragon Investor Update November 2014

/in ,

4 November 2014. Link here. The update includes: – Work begins on the new fish oil refinery; – Strengthening the SeaDragon bench; – Food industry veteran joins the SeaDragon board; – The good oil – a word from SeaDragon Chief Executive, Ross Keeley. Contact Ross Keeley SeaDragon Chief Executive Officer Telephone: 03 547 0336

Read more

Rex Bionics was winner of ‘Best Technology Award’ at the AIM Awards 2014

/in ,

Link here. 2014 AIM WINNERS – Best Technology Award. Announced at the AIM Awards ceremony on 9 October 2014.

Read more

SeaDragon strengthens leadership team

/in ,

NZX & Media Release. Link here. 1 October 2014 SeaDragon strengthens leadership team to transition to Omega 3 production Permanent marketing, sales and finance appointments reflect SeaDragon growth and strong prospects New Zealand’s largest refiner and blender of high-quality fish oils SeaDragon today announced it has expanded its leadership team with the appointment of a permanent […]

Read more

Nexvet – Two industry leaders join the Board of Directors

/in ,

DUBLIN, Ireland, MELBOURNE, Australia–‐ September 18, 2014. Link here. Veterinary biologic therapy developer Nexvet Biopharma today announced the appointments of Dr. Ashraf Hanna, M.D., Ph.D., and Dr. Joseph McCracken D.V.M., M.S., to its Board of Directors. Dr. Hanna is the Vice President of Commercial and Medical Affairs Finance at Genentech and Chief Financial Officer for the […]

Read more

Nexvet expands veterinary biologics research team

/in ,

15 September 2014. Posted in Pharma & Biopharma on 15 September, 2014. Nexvet Biopharma has added two former CSL (ASX:CSL) scientists to its veterinary biologics research team. CSL’s former director of preclinical cell biology, Dr Samantha Busfield, and former director of analytical biochemistry, Dr Dallas Hartman, have both joined Nexvet’s veterinary biologics research centre in Melbourne. The centre is designed […]

Read more

SeaDragon 2014 Annual Meeting Results and Determinations

/in ,

19 August 2014. Link here. The following resolutions were put to shareholders of SeaDragon Limited at its Annual Meeting held yesterday: 1. That Dr. Doug Wilson, retiring from office as Director of SeaDragon Limited rotation, is re-elected as a Director of SeaDragon Limited; 2. That Mr. Jeremy Curnock Cook, retiring from office as Director of SeaDragon […]

Read more

Rex Bionics awarded major research & development grant NZ Government

/in ,

11 August 2014. Link here. Rex Bionics Plc (AIM: RXB), the developer and manufacturer of hands-free robotic exoskeletons for use wheelchair users, today announces that its Auckland-based subsidiary Rex Bionics Ltd (RBL) has been awarded substantial new grant funding the New Zealand Government to support the research and development of REX 3, the platform […]

Read more

SeaDragon Update: Edison Investment Research Releases SeaDragon Update

/in ,

NZX – market Information 7 August 2014. Link here. Edison Investment Research Releases SeaDragon Update Edison Investment Research has released a SeaDragon Corporate outlook that can be found attached to this release and also available on our website. Contact Ross Keeley SeaDragon Chief Executive Officer Telephone: 03 547 0336 About SeaDragon: http://www.seadragon.co.nz SeaDragon (NZX:SEA) is Australasia’s […]

Read more